Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipids in hypertensive patients

S M Cobbe1

  • 1Department of Medical Cardiology, University of Glasgow, Scotland. stuart.cobbe@clinmed.gla.ac.uk

American Journal of Hypertension
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scottish survey of public place defibrillators.

Scottish medical journal·2010
Same author

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

European journal of epidemiology·2007
Same author

The introduction of a chest pain nurse and fast-track troponin service reduces the length of stay of patients presenting with chest pain.

Scottish medical journal·2007
Same author

Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study.

Annals of the New York Academy of Sciences·2007
Same author

Abnormal haemoglobin levels in acute coronary syndromes.

QJM : monthly journal of the Association of Physicians·2006
Same author

Reductase inhibitor monotherapy for cholesterol reduction lowered the incidence of stroke.

Evidence-based cardiovascular medicine·2005

Insulin resistance syndrome links hypertension and hyperlipidemia, common cardiovascular disease risks. Lifestyle changes are key, but optimal drug strategies for this condition require further study.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Lipidology

Background:

  • Hypertension and hyperlipidemia are significant risk factors for cardiovascular disease (CVD).
  • These conditions frequently coexist, often linked by the underlying mechanism of insulin resistance syndrome.
  • Insulin resistance syndrome is characterized by a specific lipid profile: small, dense low-density lipoprotein (LDL) particles, low high-density lipoprotein (HDL) cholesterol, and elevated triglycerides.

Purpose of the Study:

  • To explore the link between insulin resistance syndrome and the common cardiovascular risk factors of hypertension and hyperlipidemia.
  • To describe the characteristic lipoprotein profile associated with insulin resistance syndrome.
  • To review current management strategies and identify gaps in optimal pharmacotherapy.

Main Methods:

Related Experiment Videos

  • Literature review and synthesis of existing research on insulin resistance syndrome, hypertension, hyperlipidemia, and cardiovascular disease.
  • Analysis of the specific lipoprotein abnormalities in insulin resistance syndrome.
  • Evaluation of current treatment guidelines for hypertension and hyperlipidemia in the context of metabolic syndrome.

Main Results:

  • Insulin resistance syndrome serves as a unifying mechanism for hypertension and hyperlipidemia in many patients.
  • The typical lipid profile in this syndrome includes elevated triglycerides, reduced HDL cholesterol, and increased levels of small, dense LDL particles.
  • Certain antihypertensive medications, such as diuretics and beta-blockers, can potentially worsen this lipid profile.

Conclusions:

  • Insulin resistance syndrome is a critical underlying factor connecting hypertension and hyperlipidemia, increasing cardiovascular risk.
  • Initial management should focus on lifestyle modifications, including weight loss and dietary changes.
  • Further research is needed to establish the optimal antihypertensive and lipid-lowering drug strategies for patients with insulin resistance syndrome.